The majority of analyst ratings for Stoke Therapeutics in the last quarter were bullish, indicating a positive outlook for the stock. The average 12-month price target has increased significantly by 75.86%, which suggests that analysts believe the stock has potential for growth in the short term. This positive sentiment is likely to have a positive impact on the stock price.